There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Relay Therapeutics (RLAY – Research Report) and Instil Bio (TIL – Research Report) with bullish sentiments.
Relay Therapeutics (RLAY)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Relay Therapeutics today and set a price target of $30.00. The company’s shares closed last Wednesday at $10.44, close to its 52-week low of $9.67.
According to TipRanks.com, Burns is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Relay Therapeutics with a $23.00 average price target, an 117.2% upside from current levels. In a report issued on August 8, SVB Securities also initiated coverage with a Buy rating on the stock with a $18.00 price target.
See today’s best-performing stocks on TipRanks >>
Instil Bio (TIL)
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Instil Bio, with a price target of $2.00. The company’s shares closed last Wednesday at $0.49, close to its 52-week low of $0.47.
According to TipRanks.com, Kapoor is a 1-star analyst with an average return of
Instil Bio has an analyst consensus of Moderate Buy, with a price target consensus of $3.50, representing a 589.0% upside. In a report issued on August 14, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RLAY:
- Relay Therapeutics reports Q2 EPS (81c), consensus (81c)
- Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
- Relay Therapeutics initiated with an Outperform at SVB Securities
- Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023
